Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
10/20/2026
Impact: 70
Healthcare
Cantor Fitzgerald analyst Olivia Brayer Saunders has reiterated an Overweight rating on Braveheart Bio (NASDAQ: BRVE) and maintained a price target of $40 for the stock.
AI summary, not financial advice
Share: